Clinical Trial Update: Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

A Phase I trial of dasatinib in combination with protracted temozolomide for recurrent malignant glioma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Glioma
• Gliosarcoma

Drugs mentioned

• DASATINIB (Dasatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Annick Desjardins | Conditions: Glioblastoma Multiforme, Gliosarcoma | Phase 1 | Status: WITHDRAWN